Oxcarbazepine (Oxtellar XR) vs Rufinamide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline

Oxcarbazepine (Oxtellar XR)

Marketed by Supernus Pharmaceuticals

Approved in Epilepsysmall molecule
Partial signal

NCT00772603 · Phase 3 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and included 366 participants, with seizure frequency as a clinical primary endpoint. The 2,400-mg comparison significantly favored oxcarbazepine, while the 1,200-mg comparison did not, so the primary result was mixed rather than consistently positive.

Reported efficacy

Percent Change in Seizure Rate (one year): Percent Change in Seizure Rate (one year): Oxcarbazepine XR -26.3 percentage of change in seizure rate (range -100 to 344.7) (not_applicable)

Result source: NCT00908349

Rufinamide

Marketed by Eisai and partners

Approved in Epilepsysmall molecule
Partial signal

NCT00334958 · Phase 3 · completed

This randomized, double-blind, placebo-controlled Phase 3 study gave adjunctive rufinamide 3,200 mg/day or placebo to adolescents and adults with refractory partial-onset seizures (357 randomized). Its single registered primary endpoint was the percentage change in total partial seizure frequency per 28 days. The median reduction was 23.25% with rufinamide and 9.80% with placebo, and the peer-reviewed paper reports p = 0.007, so the primary endpoint was met. The registry posts the same medians but no statistical test; the p-value comes from Biton et al., Epilepsia 2011.

The p-value comes from the peer-reviewed paper (Biton et al., Epilepsia 2011); ClinicalTrials.gov posts the medians with no statistical analysis.

Reported efficacy

Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase (Baseline, Days 13 to 96): Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis). (met)

Result source: NCT00334958

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointOxcarbazepine (Oxtellar XR)Rufinamide
Seizure frequency, % change—Not reported—Not reported
50% responder rate50% vs 34%+16 vs placebo2400 mg/day · wk 16 · n 109NCT00772603
1 other result
  • 44% vs 34% 1200 mg/day · wk 16 · n 111 · Phase 3 · secondary NCT00772603
—Not reported
Seizure freedom—Not reported—Not reported

Seizure frequency, % change

Oxcarbazepine (Oxtellar XR)
—Not reported
Rufinamide
—Not reported

50% responder rate

Oxcarbazepine (Oxtellar XR)
50% vs 34%+16 vs placebo2400 mg/day · wk 16 · n 109NCT00772603
1 other result
  • 44% vs 34% 1200 mg/day · wk 16 · n 111 · Phase 3 · secondary NCT00772603
Rufinamide
—Not reported

Seizure freedom

Oxcarbazepine (Oxtellar XR)
—Not reported
Rufinamide
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Oxcarbazepine (Oxtellar XR): 4 of 4 rows · Rufinamide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOxcarbazepine (Oxtellar XR)Rufinamide
Dropout rate
42.3%2400 mg/daya
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 2 more results
32.8%1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
16.4%
NCT00908349 · Phase 3 · monotherapy
21%b
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
show 3 more results
13.8%
NCT01146951 · Phase 3 · monotherapy
40%
NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
24.1%
NCT01151540 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
30.1%2400 mg/daya
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 2 more results
14.8%1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
4.7%
NCT00908349 · Phase 3 · monotherapy
15.3%b
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
show 3 more results
13.8%
NCT01146951 · Phase 3 · monotherapy
12%
NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
7.4%
NCT01151540 · Phase 3 · registry result, not featured evidence
Serious AEs
8.1%2400 mg/daya
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 2 more results
5.7%1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
8.4%
NCT00908349 · Phase 3 · monotherapy
3.4%b
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
show 3 more results
3.4%
NCT01146951 · Phase 3 · monotherapy
40%
NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
16.7%
NCT01151540 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
2400 mg/daya
dizziness 40.7% (placebo 14.9%)
headache 15.4% (placebo 7.4%)
vomiting 15.4% (placebo 9.1%)
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 2 more results
1200 mg/day
dizziness 19.7% (placebo 14.9%)
somnolence 11.5% (placebo 9.1%)
diplopia 9.8% (placebo 4.1%)
NCT00772603 · Phase 3 · Epilepsy · phase 3
dizziness 15.4%
headache 11.2%
diplopia 9.3%
NCT00908349 · Phase 3 · monotherapy
b
dizziness 26.7% (placebo 8.3%)
headache 16.5% (placebo 12.8%)
fatigue 15.3% (placebo 10%)
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
show 3 more results
nasopharyngitis 31% (placebo 30%)
status epilepticus 27.6% (placebo 16.7%)
decreased appetite 20.7% (placebo 6.7%)
NCT01146951 · Phase 3 · monotherapy
upper respiratory tract infection 28%
vomiting 28%
somnolence 20%
NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
nasopharyngitis 48.1%
status epilepticus 40.7%
somnolence 25.9%
NCT01151540 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.
  2. bPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Oxcarbazepine (Oxtellar XR)

Seizure 50 50% (n=109) vs 34% (n=117) placebo @ 16wk2400 mg/day
responder rate · % of participants
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 1 more result
44% (n=111) vs 34% (n=117) placebo @ 16wk1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
Seizure Free 14% (n=111) vs 4% (n=117) placebo @ 16wk2400 mg/day
absolute value · percentage points
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 1 more result
6% (n=109) vs 4% (n=117) placebo @ 16wk1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
Seizure Free 17% (n=88) vs 7% (n=109) placebo @ 12wk2400 mg/day
absolute value · percentage points
Maintenance
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 1 more result
4% (n=97) vs 7% (n=109) placebo @ 12wk1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3

Rufinamide

Seizure Frequency 50 32.5% (n=160) vs 14.3% (n=175) placebo @ 14wk
responder rate · % of participants
Maintenance
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
Tonic-atonic Seizure 50% Reduction 25% (n=28) vs 6.7% (n=30) placebo @ 12wk
event count · % of participants
Yes (50% Reduction Achieved)
NCT01146951 · Phase 3 · monotherapy · converted to % from 7 Participants as posted
Drop Seizure Frequency -39.3% (n=46) @ 12wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 12
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -40.6% (n=46) @ 24wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 24
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -46.8% (n=46) @ 32wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 32
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -47.6% (n=46) @ 40wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 40
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -36.05% (n=46) @ 52wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 52
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -47.7% (n=46) @ 12wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 12
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -48.9% (n=46) @ 24wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 24
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -50.6% (n=46) @ 32wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 32
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -52% (n=46) @ 40wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 40
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -47.35% (n=46) @ 52wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 52
NCT01151540 · Phase 3 · registry result, not featured evidence

+ 5 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Oxcarbazepine (Oxtellar XR)'s landscape · Rufinamide's landscape